NCT01639027 - Drotaverine to Shorten the Length of Labor | Biotech Hunter

Enrollment

352

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

January 31, 2013

Conditions

Prolonged First Stage of LaborFailure of Cervical Dilation as Antepartum ConditionLabor PainMild Birth Asphyxia, APGAR 4-7

Interventions

DRUG

Drotaverine

40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.

DRUG

Placebo

Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.

Trial Locations (1)

Labor at the delivery unit of Ain Shams Maternity Hospital, Al ‘Abbāsīyah

All Listed Sponsors

lead

Ain Shams Maternity Hospital

OTHER